Boston Scientific Cleared For Next-Gen Deep Vein Thrombosis Catheter
This article was originally published in The Gray Sheet
A year after Boston Sci bought Bayer's interventional unit, Medrad, the company says it has received a 510(k) clearance for its ZelanteDVT catheter to be used with its AngioJet Ultra Console to treat deep vein thrombosis as mechanical – rather than drug – DVT treatments are gaining more attention.
You may also be interested in...
Randomized trial results show pharmacomechanical, catheter-directed thrombolysis does not reduce the development of post-thrombotic syndrome in patients treated for deep-vein thrombosis. The study’s investigator suggests limiting the procedure to treatment of large iliofemoral blood clots causing major symptoms in patients who are at low risk of bleeding.
Manufacturers of UK personal care products watch out, the Competition and Markets Authority is on the look-out for false, exaggerated and/or vague sustainability claims, and may be targeting bigger players to make an example for the rest of the sector. And consumer health might be next. HBW Insight returns to advice from marketing expert Jo Stephenson on how to avoid greenwashing, based on the CMA's own extensive Green Claims Code.
One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers in 2023, beyond which the agency is keen to pursue a new fees and charges plan.